International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 2 , Pages 343-352 , 1 June 2001

Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study

  • Oda B Wijers, M.D.

      Affiliations

    • Department of Radiation Oncology, University Hospital Rotterdam–Daniel, Rotterdam, The Netherlands
    • ,
  • Peter C Levendag, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University Hospital Rotterdam–Daniel, Rotterdam, The Netherlands
    • Corresponding Author InformationReprint requests to: Professor Peter C. Levendag, M.D., Ph.D., Department of Radiation Oncology, University Hospital Rotterdam–Daniel, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands. Tel: +31-10-4391366; Fax: +31-10-4391013
    • ,
  • Erik R.E Harms (D.D.S.)

      Affiliations

    • Department of Dental Oncology and Maxillofacial Prosthetics, University Hospital Rotterdam–Daniel, Rotterdam, The Netherlands
    • ,
  • A.M Gan-Teng

      Affiliations

    • Department of Dental Oncology and Maxillofacial Prosthetics, University Hospital Rotterdam–Daniel, Rotterdam, The Netherlands
    • ,
  • Paul I.M Schmitz, Ph.D.

      Affiliations

    • Department of Medical Statistics, University Hospital Rotterdam–Daniel, Rotterdam, The Netherlands
    • ,
  • W.D.H Hendriks, M.D., Ph.D.

      Affiliations

    • Department of Medical Microbiology, Medical Center Rijnmond-Zuid, Rotterdam, The Netherlands
    • ,
  • Erik B Wilms (Pharm.D.)

      Affiliations

    • Department of Pharmacy, University Hospital Rotterdam–Daniel, Rotterdam, The Netherlands
    • ,
  • Henri van der Est

      Affiliations

    • Department of Radiation Oncology, University Hospital Rotterdam–Daniel, Rotterdam, The Netherlands
    • ,
  • Leo L Visch (D.D.S.)

      Affiliations

    • Department of Dental Oncology and Maxillofacial Prosthetics, University Hospital Rotterdam–Daniel, Rotterdam, The Netherlands

,Accepted 11 December 2000.

References 

  1. Berger AM, Kilroy TJ. Oral complications of cancer therapy. In:  Berger A,  Portenoy RK,  Weissman DE editor. Principles and practice of supportive oncology. Philadelphia, New York: Lippincott-Raven Publishers; 1998;p. 223–236
  2. Cooper JS, Fu K, Marks J, Silverman S. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys. 1995;31:1141–1164
  3. Scully C, Epstein JB. Oral health care for the cancer patient. Oral Oncol Eur J Cancer. 1996;32B:281–292
  4. Pavy JJ, Denekamp J, Letschert B, et al.  EORTC late effects working group. Late effects toxicity scoring (the SOMA scale). Radiother Oncol. 1995;35:11–15
  5. Thames HD, Bentzen SM, Turesson I, et al.  Time-dose factors in radiotherapy (A review of the human data). Radiother Oncol. 1990;19:219–235
  6. Awwad HK, Khafagy Y, Barsoum M, et al.  Accelerated versus conventional fractionation in the postoperative radiation of locally advanced head and neck cancer (Influence of patient tumour proliferation). Radiother Oncol. 1992;25:261–266
  7. Cox JD, Pajak TF, Marcial VA, et al.  Interruptions adversely affect local control and survival with hyperfractionated radiation therapy for carcinomas of the upper respiratory and digestive tracts. New evidence of accelerated proliferation from Radiation Therapy Oncology Group protocol 8313. Cancer. 1992;68:2744–2748
  8. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23:457–467
  9. Horiot JC, Le Fur R, N’Guyen T, et al.  Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma (Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy). Radiother Oncol. 1992;25:231–241
  10. Bentzen SM, Ruifrok ACC, Thames HD. Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck (Clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy). Radiother Oncol. 1996;38:89–101
  11. Horiot JC, Bontemps P, van den Bogaert W, et al.  Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers (Results of the EORTC 22851 randomized trial). Radiother Oncol. 1997;44:111–121
  12. Overgaard J, Sand Hansen H, Overgaard M, et al.  Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck. A randomized multicenter study of 5 versus 6 fractions per week—report from the DAHANCA 7 trial (Abstr.). Int J Radiat Oncol Biol Phys. 1997;39:188
  13. Peters LJ, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer—the time factor. Int J Radiat Oncol Biol Phys. 1997;39:831–836
  14. Allal AS, de Pree C, Dulguerov P, et al.  Avoidance of treatment interruption (An unrecognized benefit of accelerated radiotherapy in oropharyngeal carcinomas?). Int J Radiat Oncol Biol Phys. 1999;45:41–45
  15. Barker G, Loftus L, Cuddy P, et al.  The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol. 1991;71:288–293
  16. Carl W, Emrich LS. Management of oral mucositis during local radiation and systemic chemotherapy (A study of 98 patients). J Prosthet Dent. 1991;66:361–369
  17. Sonis S, Clark J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology. 1991;5:11–18
  18. Jansma J, Vissink A, Spijkervet FKL, et al.  Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer. 1992;70:2171–2180
  19. Feber T. Management of mucositis in oral irradiation. Clin Oncol. 1996;8:106–111
  20. Symonds RP. Treatment-induced mucositis (An old problem with new remedies). Br J Cancer. 1998;77:1689–1695
  21. Plevová P. Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis (A review). Oral Oncol. 1999;35:453–470
  22. Epstein JB, Stevenson-Moore P, Jackson S, et al.  Prevention of oral mucositis in radiation therapy (A controlled study with benzydamine hydrochloride rinse). Int J Radiat Oncol Biol Phys. 1989;16:1571–1575
  23. Samaranayake LP, Robertson AG, MacFarlane TW, et al.  The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clin Radiology. 1988;39:291–294
  24. Spijkervet FKL, van Saene HKF, Panders AK, et al.  Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surg Oral Med Oral Pathol. 1989;67:154–161
  25. Ferretti GA, Raybould TP, Brown AT, et al.  Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis (A randomized double-blind trial). Oral Surg Oral Med Oral Pathol. 1990;69:331–338
  26. Foote RL, Loprinzi CL, Frank AR, et al.  Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol. 1994;12:2630–2633
  27. Epstein JB, Wong FLW. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys. 1994;28:693–698
  28. Makkonen TA, Boström P, Vilja P, et al.  Sucralfate mouth washing in the prevention of radiation induced mucositis (A placebo-controlled double blind randomized study). Int J Radiat Oncol Biol Phys. 1994;30:177–182
  29. Franzén L, Henriksson R, Littbrand B, Zackrisson B. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. A double-blind placebo-controlled study. Acta Oncologica. 1995;34:219–223
  30. Meredith R, Salter M, Kim R, et al.  Sucralfate for radiation mucositis (Results of a double-blind randomized trial). Int J Radiat Oncol Biol Phys. 1997;37:275–279
  31. Lievens Y, Haustermans K, van den Weyngaert D, et al.  Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol. 1998;47:149–153
  32. Cengiz M, Özyar E, Öztürk D, et al.  Sucralfate in the prevention of radiation-induced oral mucositis. J Clin Gastroenterol. 1999;28:40–43
  33. Huang E, Leung SW, Wang CJ, et al.  Oral glutamine to alleviate radiation-induced oral mucositis (A pilot randomized trial). Int J Radiat Oncol Biol Phys. 2000;46:535–539
  34. Etiz D, Erkal HS, Serin M, et al.  Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncology. 2000;36:116–120
  35. Spijkervet FKL, van Saene HKF, Panders AK, Vermey A. Colonisation index of the oral cavity (A novel technique for monitoring colonisation defense). Microbiol Ecol Health and Dis. 1989;2:145–151
  36. Spijkervet FKL, van Saene HKF, van Saene JJM, et al.  Mucositis prevention by selective elimination of oral flora in irradiated head and neck cancer patients. J Oral Pathol Med. 1990;19:486–489
  37. Spijkervet FKL, van Saene HKF, van Saene JJM, et al.  Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol. 1991;46:167–173
  38. van Saene HK, Martin MV. Do microorganisms play a role in irradiation mucositis?. Eur J Clin Microbiol Infect Dis. 1990;9:861–863
  39. Martin MV, van Saene HKF. The role of oral microorganisms in cancer therapy. Oral Maxillofac Surg Infect. 1992;2:81–84
  40. Martin MV. Irradiation mucositis (A reappraisal). Oral Oncol Eur J Cancer. 1993;29B:1–2
  41. Kaanders JHAM, Pop LAM, Muytens HL, et al.  Topical administration of antimicrobial agents to prevent irradiation mucositis of the oral cavity and oropharynx (A pilot study). Radiat Oncol Invest. 1995;2:283–290
  42. Symonds RP, McIlroy P, Khorrami J, et al.  The reduction of radiation mucositis by selective decontamination antibiotic pastilles (A placebo-controlled double-blind trial). Br J Cancer. 1996;74:312–317
  43. Okuno SH, Foote RL, Loprinzi CL, et al.  A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer. 1997;5:2193–2199
  44. Sonis ST. Mucositis as a biological process (A new hypothesis for the development of chemotherapy-induced stomatotoxicity). Oral Oncol. 1998;34:39–43
  45. Loury DJ, Embree JR, Steinberg DA, et al.  Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;87:544–551
  46. Maciejewski B, Withers HR, Taylor JMG, Hliniak A. Dose fractionation and regeneration for cancer of the oral cavity and oropharynx. Part 2. Normal tissue responses (Acute and late effects). Int J Radiat Oncol Biol Phys. 1990;18:101–111
  47. van der Schueren E, van den Bogaert W, Vanuytsel L, van Limbergen E. Radiotherapy by multiple fractions per day (MFD) in head and neck cancer (Acute reactions of skin and mucosa). Int J Radiat Oncol Biol Phys. 1990;19:301–311
  48. Trotti A, Klotch D, Endicott J, et al.  A prospective trial of accelerated radiotherapy in the postoperative treatment of high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1993;26:13–21
  49. Kaanders JHAM, Ang KK. Early reactions as dose-limiting factors in radiotherapy. Semin Radiat Oncol. 1994;4:55–67
  50. Adelstein DJ, Saxton JP, van Kirk MA, et al.  Continuous course radiation therapy and concurrent combination chemotherapy for squamous cell head and neck cancer. Am J Clin Oncol. 1994;17:369–373
  51. Denham JW, Hamilton CS, Simpson SA, et al.  Acute reaction parameters for human oropharyngeal mucosa. Radiother Oncol. 1995;35:129–137
  52. Geara FB, Peters LJ, Ang KK, et al.  Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. Int J Radiat Oncol Biol Phys. 1996;35:455–462
  53. Maciejewski B, Skladowski K, Pilecki B, et al.  Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity. Radiother Oncol. 1996;40:137–145
  54. Denham JW, Abbott RL. Concurrent cisplatin, infusional fluoruracil, and conventionally fractionated radiation therapy in head and neck cancer (Dose-limiting mucosal toxicity). J Clin Oncol. 1991;9:453–463
  55. Dische S, Saunders M, Barrett A, et al.  A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123–136
  56. Jackson SM, Weir LM, Hay JH, et al.  A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;43:39–46
  57. Kaanders JHAM, van der Kogel AJ, Ang KK. Altered fractionation (Limited by mucosal reactions?). Radiother Oncol. 1999;50:247–260
  58. Spijkervet FKL, Saene HKF, Panders AK, et al.  Scoring irradiation mucositis in head and neck cancer patients. J Oral Pathol Med. 1989;18:167–171
  59. Sonis ST, Eilers JP, Epstein JB, et al.  Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer. 1999;85:2103–2113
  60. Trott KR. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys. 1990;19:1071–1075
  61. Denham JW, Walker QJ, Lamb DS, et al.  Mucosal regeneration during radiotherapy. Radiother Oncol. 1996;41:109–118
  62. Bernier J, Thames HD, Smith CD, Horiot JC. Tumor response, mucosal reactions and late effects after conventional and hyperfractionated radiotherapy. Radiother Oncol. 1998;47:137–143
  63. Makkonen T, Borthen L, Heimdahl A, et al.  Oropharyngeal colonisation with fungi and gram-negative rods in patients treated with radiotherapy of the head and neck. Br J Oral Maxillofac Surg. 1989;27:334–340
  64. Verdi CJ. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Saf. 1993;9:185–195
  65. Rahn R, Adamietz IA, Boettcher HD, et al.  Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology. 1997;195(Suppl. 2):57–61
  66. Adamietz IA, Rahn R, Böttcher HD, et al.  Wertigheit der prophylaktischen Mundspüling mit PVP-Iodlösung. Prophylaxe der radiochemotherapeutisch bedingten Mukositis. Strahlenther Onkol. 1998;174:149–155
  67. Adamietz IA, Rahn R, Böttcher HD, et al.  Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Support Care Cancer. 1998;6:373–377
  68. Rugg T, Saunders MI, Dische S. Smoking and mucosal reactions to radiotherapy. Br J Radiol. 1990;63:554–556
  69. Dörr W, Dölling-Jochem I, Baumann M, et al.  Therapeutische Beeinflussung der radiogenen oralen Mukositis. Strahlenther Onkol. 1997;173:183–192
  70. Mills EED. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. Br J Cancer. 1988;57:416–417
  71. Abdelaal AS, Barker DS, Fergusson MM. Treatment for irradiation-induced mucositis. (letter) Lancet. 1989;1:97
  72. Matejka M, Nell A, Kment G, et al.  Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg. 1990;28:89–91
  73. Osaki T, Ueta E, Yoneda K, et al.  Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azelastine) with other antioxidants. Head Neck. 1994;16:331–339
  74. Leborgne JH, Leborgne F, Zubizarreta E, et al.  Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol. 1997;47:145–148
  75. Mose S, Adamietz IA, Saran F, et al.  Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis?. Am J Clin Oncol. 1997;20:407–411
  76. Oguchi M, Shikama N, Sasaki S, et al.  Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis. Int J Radiat Oncol Biol Phys. 1998;40:1033–1037
  77. Maciejewski B, Zajusz A, Pilecki B, et al.  Acute mucositis in the stimulated oral mucosa of patients during radiotherapy for head and neck cancer. Radiother Oncol. 1991;22:7–11
  78. Dörr W, Jacubek A, Kummermehr J, et al.  Effects of stimulated repopulation on oral mucositis during conventional radiotherapy. Radiother Oncol. 1995;37:100–107
  79. Epstein JB, Emerton S, Guglietta A, Le N. Assessment of epidermal growth factor in oral secretions of patients receiving radiation therapy for cancer. Oral Oncol. 1997;33:359–363
  80. Ruifrok ACC, McBride WH. Growth factors (Biological and clinical aspects). Int J Radiat Oncol Biol Phys. 1999;43:877–881
  81. Danilenko DM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol. 1999;27:64–71
  82. Wardley AM, Scarffe JH. Role of granulocyte macrophage colony stimulating factor in chemoradiotherapy induced oral mucositis. J Clin Oncol. 1996;14:1741–1742
  83. Kannan V, Bapsy PP, Anantha N, et al.  Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiat Oncol Biol Phys. 1997;37:1005–1010
  84. Nicolatou O, Sotiropoulou-Lontou A, Skarlatos J, et al.  A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy (A preliminary report). Int J Radiat Oncol Biol Phys. 1998;42:551–556
  85. Wagner W, Alfrink M, Haus U, et al.  Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer. Anticancer Res. 1999;19:799–804
  86. Koukourakis MI, Fordellis CS, Giatromanolaki A, et al.  Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis. Clinical Cancer Research. 1999;5:3970–3976
  87. Makkonen TA, Minn H, Jekunen A, et al.  Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis (A prospective randomized study). Int J Radiat Oncol Biol Phys. 2000;46:525–534
  88. Hospers GAP, Eisenhauer EA, de Vries EGE. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer. 1999;80:629–638
  89. Buntzel J, Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 1998;9:505–509
  90. Buntzel J, Schuth J, Kuttner K, Glatzel M. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer. 1998;6:155–160
  91. McDonald S, Meyerowitz C, Smudzin T, Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary dysfunction. Int J Radiat Oncol Biol Phys. 1994;29:747–754

PII: S0360-3016(01)01444-4

International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 2 , Pages 343-352 , 1 June 2001

Article Tools

* Image Usage & Resolution